Last reviewed · How we verify
NCT05228652: CAH-MaS
Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
trial testing Questionnaire in Adrenal Hyperplasia, Congenital in 61 participants. Status unknown.
1 February 2024
Quick facts
| Lead sponsor | Manchester University NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 61 |
| Start date | 28 February 2022 |
| Primary completion | 1 February 2024 |
| Estimated completion | 1 February 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Questionnaire
Conditions studied
- Adrenal Hyperplasia, Congenital — all drugs for Adrenal Hyperplasia, Congenital →
Sponsor
Manchester University NHS Foundation Trust
Who can join
Adults 16 to 100, any sex, with Adrenal Hyperplasia, Congenital. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a questionnaire study involving women and young girls affected by Congenital Adrenal Hyperplasia (CAH) and their parents. The aim is to obtain information regarding the outcomes of conservative or surgical management of CAH at the Royal Manchester Children's Hospital (RMCH) in the last 50 years, with specific reference to genital appearance and its impact on patient's social/physical/emotional/sexual outcomes. The study wants also investigate on the individuals and parental perspectives on the proposal to take away the option of early childhood surgery for girls with this condition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05228652
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire
Trials testing the same drug.
- NCT04466371 — Perceptions of Undergraduate Students and Teaching Staff on Online Teaching · suspended
- NCT07089953 — Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomiz · NA · not yet recruiting
- NCT07418775 — Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma · not yet recruiting
- NCT07226804 — Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules · not yet recruiting
- NCT07532954 — The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support · recruiting
Other Manchester University NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07057284 — DENTOFACIAL-PBT Stage 2 - Feasibility Study · enrolling by invitation
- NCT06972238 — Glucose Levels in Acute Pancreatitis and the Impact of Insulin Depletion and Bacterial Endotoxaemia · not yet recruiting
- NCT06681545 — Exploring the Lived Experience of Young Adults With Severe Asthma · recruiting
- NCT07049263 — Disparities In Access to the Northwest Ambulance Service During Pregnancy, Birth and Postpartum Period and Its Associati · active not recruiting
- NCT06561334 — Spasmodic Dysphonia Interviews · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05228652 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Manchester University NHS Foundation Trust
- Last refreshed: 13 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05228652.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing